Jefferson: A day of reckoning for one of San Antonio s worst economic development deals?
expressnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from expressnews.com Daily Mail and Mail on Sunday newspapers.
The Life Sciences Report – June 2021 | Wilson Sonsini Goodrich & Rosati
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
How Rani Therapeutics’ robotic pill could change subcutaneous injection treatment
A new auto-injecting pill might soon become a replacement for subcutaneous injection treatments.
The idea for this so-called robotic pill came out of a research project around eight years ago from InCube Labs a life sciences lab operated by Rani Therapeutics Chairman and CEO Mir Imran, who has degrees in electrical and biomedical engineering from Rutgers University. A prominent figure in life sciences innovation, Imran has founded more than 20 medical device companies and helped develop the world’s first implantable cardiac defibrillator.
In working on the technology behind San Jose-based Rani Therapeutics, Imran and his team wanted to find a way to relieve some of the painful side effects of subcutaneous (or under-the-skin) injections, while also improving the treatment’s efficacy. “The technology itself started with a very simple thesis,” said Imran in an interview. “We thought, why c
Rani Therapeutics Raises $69 Million Series E To Advance Clinical Trials And Manufacturing Of Robotic Pill
News provided by
Share this article
Share this article
SAN JOSE, Calif., Dec. 10, 2020 /PRNewswire/ Rani Therapeutics, a clinical-stage biopharmaceutical company and developer of the RaniPill™ robotic pill, today announced that it has raised $69 million in a Series E financing, bringing the total funding to $211 million. BofA Securities acted as financial advisor to the company.
The company s platform technology converts injectable drugs like PTH and adalimumab into pills. The market potential of the RaniPill™ to replace injectable biologics with oral versions, represents multiple billion-dollar opportunities for diabetes, arthritis, psoriasis, hemophilia and other diseases.